Persimmune Is A Clinical Stage Immunotherapy Company Whose Mission Is To Provide Cancer Patients With Optimized Immunotherapy That Is Personalized On The Basis Of Their Own Unique Tumor Signaturejust As No Two People Are Alikeno Two Cancers Are Exactly Alikebecause Of Thisthe Same Immunotherapy Treatment That Works For One Patient May Not Work Well In Anotherto Address This Treatment Disparitypersimmune S Proprietary Protocolpersonal Adoptive Cellular Therapy For Neoantigenspactnidentifies The Dna Alterations Present In The Cancer Cells Of Each Patient And Generates Enrichedtestedhighly Specific T Cells That Effectively Kill The Patient S Tumor Cellsthese Are The Patient S Own Cellsand Are Not Edited Or Genetically Engineered Which Means Patients Will Experience Far Less Side Effects Than From Chemotherapy Or Other Methods Of Immunotherapy Personalized Adoptive Cellular Therapy Has The Potential To Transform The Field Of Cancer Treatment By Providing Safehighly Tolerableeffective Immunotherapy To Cancer Patientspersonal Immunotherapy Because No Two Patients Are Exactly Alike Persimmune Is Currently Accepting Patients For The Phase 1 Clinical Trial Of Its Personalized Adoptive Cell Transfer Technology Targeting Neoantigenspactn The Trial Provides A Therapy For Early And Late Stage Patients Of Myelodysplastic Syndromemds
No conferences found for this company.
| Company Name | Persimmune Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
